GLP-1 weight loss drugs linked to heightened GI risks, says new study

FHS
October 5, 2023
11:04 pm

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

CentralReach Acquires Behavior Science Technology inc

What You Should Know: – CentralReach, the leading provider of Autism and IDD Care software for ABA, multidisciplinary, and special education, today announced the acquisition of

September 18, 2024

Heart failure triggers multimorbidity by altering stem cells, study reveals

Researchers identified that heart failure (HF) promotes multimorbidity by altering hematopoietic stem cells (HSCs) to produce pro-inflammatory macrophages, increasing vulnerability in multiple organs. The study

May 28, 2024

SKAN Group reaches its targets in the first half of 2024 – Biotech Investments

SKAN AG / Key word(s): Half Year Results 20-Aug-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer

August 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.